Melanotan I — reference
An alpha-MSH analogue (afamelanotide) that stimulates melanin production; FDA-approved as an implant for a rare light-sensitivity disorder.
Regulatory status
FDA-Approved (labeled use). FDA-approved as SCENESSE for erythropoietic protoporphyria — a rare condition. The injectable peptide sold online for tanning is not that product and is not approved.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~1 hour (as solution injection); differs from the FDA-approved slow-release implant form (afamelanotide/Scenesse). Don't conflate implant duration with plasma half-life if you cite the FDA-approved form.
This figure is tagged Limited data in our evidence system. The available data does not support a confident single figure, so this entry is flagged accordingly. Read any curve built from it as illustrative only. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Melanotan I FDA-approved?
What is the half-life of Melanotan I?
How reliable is that half-life figure?
What cautions are associated with Melanotan I?
Does Peptide Plug publish dosing for Melanotan I?
Does Peptide Plug sell Melanotan I?
Related tools
Free, no account required.